South Korea and Pfizer Collaborate on Cancer Research with KRIBB

South Korea's state-run bioscience laboratory, the Korea Research Institute of Bioscience and Biotechnology (KRIBB), has partnered with the pharmaceutical giant Pfizer Inc. to develop new cancer treatment materials. The collaborative project, which will span two years, aims to find candidate materials for liver and stomach cancer treatments. KRIBB will provide its extensive database on genes and proteins associated with liver and stomach cancer, while Pfizer will contribute antibodies and other compounds that could target cancerous growths. The partnership is seen as a significant step forward in accelerating cancer research in South Korea.

Key Takeaways:

The two-year project will involve the joint search for candidate materials to treat liver and stomach cancer, leveraging KRIBB's gene database and Pfizer's expertise in developing new drugs.
Pfizer will provide antibodies and other compounds to KRIBB, which will utilize its extensive database on genes and proteins associated with liver and stomach cancer.
KRIBB has collected approximately 2,500 tissue samples over the last decade, which will be used to advance research and identify potential targets for cancer treatment.
The project has the potential to become a new model for finding new drugs in South Korea, with Pfizer recognizing the competence of local laboratories and scientists.
Pfizer has a proven track record of developing innovative treatments for cancer, including its Sutent drug, which targets cellular reproduction and cuts off tumor blood supply.

Statistics:

2,500: The number of tissue samples collected by KRIBB over the last decade.
2007: The year in which Pfizer reported earnings of US$48.4 billion, with R&D investment reaching US$8.1 billion.
18-05 1201: The timestamp of the press release announcing the partnership between KRIBB and Pfizer.

Sources:

(Yonhap) {no date mentioned}
Korea Research Institute of Bioscience and Biotechnology (KRIBB)